Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Viatris Launches New Headquarters in Tokyo
The Viatris group launched a new head office within the building of Holland Hills Mori Tower in Toranomon, a business district of Minato-ku, Tokyo, effective April 1, integrating all head offices of its group companies, it said on April 5.…
To read the full story
Related Article
- Viatris Japan to Go After Drugs in All Phases of Life Cycle, Group Consolidation by Year-End: Chief
September 26, 2023
- As Pfizer/Mylan’s Generics Merger Closed, 4 Viatris Group Firms to Operate Together in Japan
November 18, 2020
- Pfizer Renames Japan Subsidiaries as Mylan Deal Set to Close Soon; Upjohn Biz Now Separate
October 7, 2020
- In Japan Too, Pfizer and Mylan Prepping for Pending Viatris Integration
February 12, 2020
BUSINESS
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
- Nipro Pharma Recalls Topical Drugs over Long-Running Manufacturing Deviations
July 16, 2026
- JCR to File DMD Drug Givinostat in Japan by End-2026
July 16, 2026
- Daiichi Sankyo Healthcare to Take Over Claritin EX Sales in Japan
July 16, 2026
- Maruishi Set to Secure Japan Rights to Kringle’s Vocal Fold Scar Drug
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…